Skip to main content
OpenTrials

Clinical trial condition

Neoplasms, Plasma Cell

Explore clinical trials studying Neoplasms, Plasma Cell. Study availability and eligibility vary by location and protocol.

2,604 public trials 547 recruiting studies
Refine in advanced search Browse all conditions

Neoplasms, Plasma Cell trial results

Completed

Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL)

NCT04093596

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Banner MD Anderson Cancer Center Gilbert, Arizona, United States
  • City of Hope Duarte, California, United States
  • Stanford Cancer Institute Palo Alto, California, United States
  • Sarah Cannon/Colorado Blood Cancer Institute Denver, Colorado, United States
View Trial Details
Completed

IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients

NCT01009840

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Arizona Cancer Center Tucson, Arizona, United States
  • Blood and Marrow Transplant Group of Georgia Atlanta, Georgia, United States
  • Loyola University Medical Center Maywood, Illinois, United States
  • Indiana University Melvin and Bren Simon Cancer Center Indianapolis, Indiana, United States
View all 13 locations
View Trial Details
Completed

Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple Myeloma

NCT03934684

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Yashoda Hospital Hyderabad, Andhra Pradesh, India
  • Apollo Hospital Hyderabad, Andhra Pradesh, India
  • M S Ramaiah Memorial Hospital Bangalore, Karnataka, India
  • K L E S Dr Prabhakar Kore Hospital and Medical Research Centre Belagavi, Karnataka, India
View all 17 locations
View Trial Details
Completed

Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma

NCT05064358

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +16 more
Locations
  • GSK Investigational Site West Palm Beach, Florida, United States
  • GSK Investigational Site Kansas City, Missouri, United States
  • GSK Investigational Site New York, United States
  • GSK Investigational Site Chattanooga, Tennessee, United States
View all 77 locations
View Trial Details
Completed

First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM)

NCT04083534

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
Locations
  • Regeneron Study Site Indianapolis, Indiana, United States
  • Regeneron Study Site Ann Arbor, Michigan, United States
  • Regeneron Study Site Rochester, Minnesota, United States
  • Regeneron Study Site New York, United States
View Trial Details

Related conditions